Naloxone nasal spray (Nyxoid®) in opioid overdose: a profile of its use in the EU

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Drugs & therapy perspectives

• Publication date

  2018-03-12

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s40267-018-0498-y
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Naloxone Administration for Opioid Overdose Reversal in the Prehospital Setting: Implications for Pharmacists

  2018cited by this paper
• Naloxone dosage for opioid reversal: current evidence and clinical implications

  2018cited by this paper
• Comparing methods of naloxone administration: A narrative review.

  2017cited by this paper
• Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review

  2017cited by this paper
• Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post‐dosing: analysis of suitability for opioid overdose reversal

  2017cited by this paper
• Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study*

  2017influential reference
• Effectiveness of Scotland's National Naloxone Programme for reducing opioid‐related deaths: a before (2006–10) versus after (2011–13) comparison

  2016cited by this paper
• Preventing opioid overdose deaths with take-home naloxone.

  2016influential reference
• Are take‐home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria

  2016cited by this paper
• Cost-Effectiveness of Take Home-Naloxone for the Prevention Of Fatalities from Heroin Overdose in the UK

  2016influential reference
• Pharmacokinetic Properties and Human Use Characteristics of an FDA‐Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose

  2016cited by this paper
• Working together: Expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond.

  2015cited by this paper
• Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access

  2015cited by this paper
• Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis

  2013cited by this paper
• Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal

  2013influential reference
• Population Pharmacokinetics of Intravenous, Intramuscular, and Intranasal Naloxone in Human Volunteers

  2008cited by this paper

• No citing papers are available for this paper.